Pharmacogenomics to Drive COVID-19 Therapy for Best Outcome in a Low Resource Setting
DOI:
https://doi.org/10.21467/preprints.214Abstract
Corona virus disease 2019 (COVID-19) has taken the world by storm with global infectivity and mortality of 3.5%. Since there is no specific treatment for COVID-19, several drugs have been repurposed to combat infection, these include drugs like anti-malarial – chloroquine, hydroxychloroquine, anti- diarrheal– loperamide and antipsychotic-promazine, which have been considered to be effective inhibitors as of viral binding to ACE2 receptor. The administration of these drugs is currently random and is the key factors responsible for varied treatment response, hence genes involved in drug metabolism should be analysed before planning therapy. Genes involved in metabolism of the listed drugs are ABCB1, CYP1A2, CYP2C8, CYP2C19, CYP3A4 and CYP2D6. Unpublished pharmacogenomic data from our internal cohort (75 cases) was analyzed to predict likely-responders and non-responders to propose drugs for COVID-19 drug therapy in our population. Preliminary data from random individuals without bias indicates that both anti-malarials at standard dose will benefit 98% of our cases (in absence of co-morbidities), while 11-85% of individuals would require dose reduction/alternatives for loperamide and promazine. Anti-malarials like chloroquine, hydroxychroloquine can be prescribed for prophylaxis and as first line of therapy in absence of comorbidities. Simple genotype testing of ABCB1, CYP1A2, CYP2C19 and CYP2D6 is an indispensable tool to predict treatment outcomes of loperamide and promazine for COVID-19 patients.
Keywords:
COVID-19 Pandemic, drug-repurposing, pharmacogenomicsDownloads
References
World Health Organization. WHO coronavirus disease (COVID-19) dashboard. World Health Organization, Geneva, Switzerland. https://covid19.who.int/ Accessed. 2020 August;23.
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). InStatpearls [internet] 2020 Mar 8. StatPearls Publishing.
Senanayake SL. Drug repurposing strategies for COVID-19. 2020 J Future Drug Discovery10.4155/fdd-2020-0010
Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. MedRxiv. 2020 Jan 1.
De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S, Bestebroer TM, Van Den Hoogen BG, Neyts J, Snijder EJ. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial agents and chemotherapy. 2014 Aug 1;58(8):4875-84.
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. Journal of medical virology. 2020 May;92(5):479-90.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020 Apr 30;382(18):1708-20.
Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, Shrank WH. Pricing of monoclonal antibody therapies: higher if used for cancer. Am J Manag Care. 2018 Feb 1;24(2):109-12
Gangal N, Nagle V, Pawar Y, Dasgupta S. Reconsidering Traditional Medicinal Plants to Combat COVID-19. AIJR Preprints. 2020 Apr 15.
Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. (2003): 871-873.
Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, Sigl V, Hanada T, Hanada R, Lipinski S, Wild B. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012 Jul;487(7408):477-81.
Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. The Journal of Infection in Developing Countries. 2020 Feb 29;14(02):125-8.
Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. Journal of Antimicrobial Chemotherapy. 2015 Jun 1;70(6):1608-21.
Tunde AA. A Systematic Review on the Potency and How Safe Chloroquine is for the Treatment of COVID-19. AIJR Preprints. 2020 May 12.
National Center for Biotechnology Information. PubChem Database. Chloroquine, CID=2719, https://pubchem.ncbi.nlm.nih.gov/compound/Chloroquine (accessed on Mar 31st 2020)
Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, Ducharme J. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metabolism and Disposition. 2003 Jun 1;31(6):748-54..
Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics and Genomics. 2001 Oct 1;11(7):597-607.
Yu L, Shi D, Ma L, Zhou Q, Zeng S. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharmaceutics & drug disposition. 2013 Jul;34(5):278-87.
Kim KA, Park JY, Lee JS, Lim S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Archives of pharmacal research. 2003 Aug 1;26(8):631-7. Fan HW, Ma ZX, Chen J, Yang XY, Cheng JL, Li YB. Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC–MS/MS. Rheumatology and therapy. 2015 Dec 1;2(2):183-95.
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Mar 4;105932.
Xueting Yao, Fei Ye et al, In Vitro Antiviral Activity and Projection of Optimized DosingDesign of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clinical Infectious Diseases, ,ciaa237, https://doi.org/10.1093/cid/ciaa237
National Center for Biotechnology Information. PubChem Database. Hydroxychloroquine, CID=3652, https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxychloroquine (accessed on Mar.5229, 2020)
Somer M, Kallio J, Pesonen U, Pyykkö K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. British journal of clinical pharmacology. 2000 Jun;49(6):549-54.
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P 450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. The pharmacogenomics journal. 2005 Feb;5(1):6-13.
National Center for Biotechnology Information. PubChem Database. Loperamide,CID=3955, https://pubchem.ncbi.nlm.nih.gov/compound/Loperamide (accessed on Mar. 29, 2020)
De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S, Bestebroer TM, Van Den Hoogen BG, Neyts J, Snijder EJ. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial agents and chemotherapy. 2014 Aug 1;58(8):4875-84.
Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lötsch J. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics and Genomics. 2003 Nov 1;13(11):651-60.
National Center for Biotechnology Information. PubChem Database. Promazine, CID=4926, https://pubchem.ncbi.nlm.nih.gov/compound/Promazine (accessed on Mar. 29, 2020)
Zhang XW, Yap YL. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorganic & medicinal chemistry. 2004 May 15;12(10):2517-21.
Wójcikowski J, Pichard?Garcia L, Maurel P, Daniel WA. Contribution of human cytochrome P?450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. British journal of pharmacology. 2003 Apr;138(8):1465-74.
Varshney MM, Sharma A. An Overview on Drug Evolution and Trials on Pandemic COVID-19 Infection. AIJR Preprints. 2020 Jul 26.
Downloads
Posted
Section
Categories
License
Copyright (c) 2020 Gayatri Iyer, Syeda Zubeda, Aruna Priya Kamireddy, Qurratulain Hasan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any non-commercial use, distribution, adaptation, and reproduction in any medium is permitted as long as the original work is properly cited. However, caution and responsibility are required when reusing as the articles on the preprint server are not peer-reviewed. Readers are advised to check for the availability of any updated or peer-reviewed version.
